A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.

Area of Science:

• Hematology
• Oncology
• Medical Prognostics

Background:

• Primary myelofibrosis (PMF) is a Philadelphia chromosome-negative myeloproliferative neoplasm with highly variable clinical outcomes.
• Accurate prognostication is crucial for managing PMF heterogeneity and guiding treatment, including hematopoietic stem cell transplantation eligibility.

Purpose of the Study:

• To review established and emerging prognostic models for primary myelofibrosis.
• To provide a practical framework for risk stratification in PMF and post-essential thrombocythemia/polycythemia vera myelofibrosis.

Main Methods:

• Review of widely adopted prognostic scoring systems for PMF.
• Inclusion of models incorporating clinical, molecular, and cytogenetic features.
• Discussion of models for both primary PMF and secondary myelofibrosis.

Main Results:

• Several prognostic models exist, evolving from clinical-only to integrated molecular and cytogenetic assessments.
• Models like IPSS, DIPSS, MIPSS70, and others offer varying levels of risk stratification.
• Emerging models aim for more comprehensive prognostication in PMF.

Conclusions:

• Prognostic models are essential for managing PMF heterogeneity and guiding therapeutic strategies.
• Contemporary models leveraging molecular and cytogenetic data enhance prognostication accuracy.
• A practical approach to risk stratification aids clinical decision-making in PMF.